GlassScriptPhysician profile
Michael T Yim
NPI 1073959508
$76,602.41
in general payments reported to CMS, 2019-2025
34 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $311 · 2021: $2,685 · 2022: $8,494 · 2023: $10K · 2024: $22K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Food and Beverage: $5,553 · Travel and Lodging: $4,971 · Education: $74.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,162.74 |
| Food and Beverage | $5,552.85 |
| Travel and Lodging | $4,970.68 |
| Education | $74.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $47,775.75 | 2020-2025 | |
| Acclarent, INC | $10,586.30 | 2021-2024 | Acclarent Balloon Inflation Device, Trudi Nav Suction |
| Chitogel Limited | $6,000.00 | 2021-2022 | |
| Spirair, INC. | $4,624.30 | 2024-2025 | Septalign |
| Medtronic, INC. | $2,476.10 | 2021-2025 | Propel, Nim Vital, Stealthstation S8 Platform |
| Genzyme Corporation | $1,498.38 | 2022-2025 | |
| Depuy Synthes Sales INC. | $869.66 | 2020-2025 | Trumatch, Matrixmidface |
| Regeneron Healthcare Solutions, INC. | $375.11 | 2021-2025 | Dupixent |
| Integra Lifesciences Corporation | $350.17 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Intersect Ent, INC. | $333.91 | 2019-2021 | |
| Olympus America INC. | $303.46 | 2020-2025 | Rhino-Laryngo Videoscope, Connecting Tube, Olympus |
| Glaxosmithkline, LLC. | $252.67 | 2021-2025 | Nucala |
| Smith+Nephew, INC. | $119.07 | 2019 | |
| 3-D Matrix, INC. | $114.44 | 2022-2024 | |
| Stryker Corporation | $103.70 | 2020-2023 | Scopis Ent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $97.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.77 | 2019-2023 | |
| Genentech USA, INC. | $92.91 | 2019-2025 | Xolair |
| Leo Pharma INC. | $69.31 | 2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $65.64 | 2021-2025 | |
| Ethicon US, LLC | $52.78 | 2022 | |
| Medical Device Business Services, INC. | $48.37 | 2023 | Vapr |
| Kaleo, INC. | $45.57 | 2020-2022 | |
| Inspire Medical Systems, INC. | $36.99 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $33.68 | 2021-2023 | |
| Biocryst Pharmaceuticals, INC. | $33.16 | 2020 | |
| Optinose US, INC. | $32.50 | 2023 | |
| Axogen | $22.01 | 2021 | |
| Pharming Healthcare, INC. | $20.98 | 2020 | |
| Karl Storz Endoscopy-America | $18.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.34 | 2020 | |
| Medtronic USA, INC. | $14.17 | 2020 | |
| Metrex Research, LLC | $13.68 | 2021 | |
| Ormco Corporation | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.